Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1.

Mahmoud S AlghamriRohit ThallaRuthvik P AvvariAli DabajaAyman TaherLili ZhaoPeter J UlintzMaria G CastroPedro R Lowenstein

Published in: Neuro-oncology advances (2020)

we demonstrate that tumor mutational burden is a powerful, robust, and clinically relevant prognostic factor of MS in mIDH patients.

Keyphrases